
\mathbf{A}



Unexpanded early blastocysts Expanded blastocysts


Day 7 post IVF














Hatched blastocysts





Figure S1. Development of cumulus oocyte complexes and embryos during *in vitro* maturation and *in vitro* development post IVF. Morphology was observed under microscopy $40 \times$ and $100 \times$ for IVM and for IVD respectively. **A.** COC underwent 24 h IVM in the presence or absence of BPS (1 nM, 10 nM, 100 nM, 1 μ M or 10 μ M). Scale bar represents 100 μ m. **B.** Oocytes were subjected to IVF, and the cleavage rate was assessed 2 days after IVF. Embryos with more than 4 cells were distinguished from embryos with 2-4 cells. Scale bar represents 40 μ m C. Blastocyst rate was evaluated 7 days after IVF. Blastocysts were classified as unexpanded early, expanded or hatched. Scale bar represents 40 μ m.

Α



В




Figure S2. Western blot analysis of MAPK3/1 signalling pathway activation in oocytes after BPS exposure. COC underwent IVM for 6 h in the presence or absence of BPS (10 nM or 1 μ M). After 6-h IVM, groups of 30 oocytes were denuded. Proteins were then extracted and separated by electrophoresis on 4–12% (w:v) sodium dodecyl sulphate polyacrylamide gels. After electrotransfer to nitrocellulose membranes, the proteins were probed with anti-phospho-MAPK3/1 and anti-MAPK3/1 antibodies. **A.** Representative blots and bands are presented in this figure. **B.** Bands on the blots were quantified and the phospho/total protein ratio was calculated. Results are expressed relative to the control as mean \pm SEM of nine independent samples per condition. Different letters indicate significant differences ($p \le 0.05$).

Name	Species Specificity	Source	Supplier (Distributor, Town, Country)	Reference
MAPK3/1 (ERK1/2)	Rat	Rabbit polyclonal antibody	Cell Signaling Technology (Ozyme, Saint Quentin Yvelines, France)	9102
Phospho-MAPK3/1 (ERK1/2) (Thr202/Tyr204, D13.14.4E, XPTM)	Human	Rabbit monoclonal antibody	Cell Signaling Technology (Ozyme, Saint Quentin Yvelines, France)	4370
Vinculine	Human	Mouse monoclonal antibody	Sigma Aldrich Saint Quentin Fallavier	V9131

Table S1: Characteristics of primary antibodies used for western blotting

Table S2. Results of logistic regression analysis and presenting therefore estimated % of the model comparing all conditions at the same time on the effect of BPS during IVM on *in vitro* embryo development after *in vitro* fertilization, and taking into account both treatment and experiment effects (logistic regression model estimated % ± sem)

Conditions		Mature COC	Cleaved embryos	2-4 cells embryos	> 4 cells embryos	Blastocysts	Unexpanded early blastocysts	Expanded Blastocysts	Hatched blastocysts
Control	N	370	202	81	121	44	10	15	19
	%		57.4 ± 6.1	21.6 ± 3.1	33.6 ± 4.7	22.2 ± 3.5	3.8 ± 1.9	7.4 ± 1.9	9.4 ± 2.1
BPS 1nM	N	281	197	69	128	37	5	16	16
	%		71.7 ± 5.4	23.5 ± 3.5	45.6 ± 5.3	18.7 ± 3.2	1.8 ± 1.1	8.0 ± 2.0	8.1 ± 2.0
	<i>p</i> -value		0.0003	0.564	0.0025	0.3918	0.176	0.819	0.6474
BPS 10nM	N	298	183	79	104	26	4	12	10
	%		61.2 ± 6.1	25.6 ± 3.6	33.3 ± 4.8	14.2 ± 2.9	1.9 ± 1.2	6.4 ± 1.9	5.4 ± 1.7
	<i>p</i> -value		0.335	0.227	0.942	0.0458	0.246	0.720	0.150
BPS 100nM	N	296	167	62	105	33	7	11	15
	%		55.0 ± 6.3	19.6 ± 3.1	33.6 ± 4.8	20.4 ± 3.6	4.3 ± 2.3	6.5 ± 2.0	8.9 ± 2.3
	<i>p</i> -value		0.561	0.537	0.980	0.674	0.786	0.752	0.882
BPS 1uM	N	319	152	77	75	19	6	8	5
	%		45.9 ± 6.3	23.0 ± 3.3	21.8 ± 3.8	12.1 ± 2.9	3.3 ± 1.9	5.1 ± 1.8	3.3 ± 1.5
	<i>p</i> -value		0.0041	0.657	0.0008	0.0168	0.814	0.382	0.0315
BPS 10uM	N	321	163	74	89	24	7	12	5
	%		50.7 ± 6.3	22.2 ± 3.3	26.7 ± 4.3	14.7 ± 3.1	3.6 ± 1.9	7.2 ± 2.1	3.1 ± 1.4
	p-value		0.0923	0.842	0.0574	0.0715	0.918	0.953	0.0212

N: Number of samples ; % is the % estimated by the logistic regression model \pm sem ; p-value is the logistic regression p-value of the comparison to the control condition ; bold characters indicate significant differences $p \le 0.05$; italic and bold characters indicate tendencies 0.05